News
September 8, 2009 – Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, said last week it received $36 million in financing to fund the European commercialization and U.S. premarket approval (PMA) clinical study of the company’s TactiCath force-sensing ablation catheter.
September 08, 2009
Technology
September 8, 2009 – Actelion Pharmaceuticals U.S. Inc. recently announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis, for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH).
September 08, 2009News
September 8, 2009 – Siemens Healthcare and SurgiVision Inc. today announced an agreement for the codevelopment and commercialization of a real-time magnetic resonance image (MRI)-guided cardiac electrophysiology (EP) system.
September 08, 2009Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
Technology
The HI-TORQUE Balance Middle Weight (BMW) Universal II Guide Wire offers the same performance of Abbott’s HT BMW UNIVERSAL wire, but includes the two advanced coating technologies and better coating durability for longer procedures
September 03, 2009
Technology
The Perclose ProGlide 6 Fr. Suture-Mediated Closure System delivers a secure, reliable vessel closure to provide complete tissue apposition resulting in primary healing, reduces time to hemostasis, ambulation and discharge, and does not have any reaccess restrictions.
September 03, 2009
News
September 3, 2009 – Percutaneous cardiac valve maker Evalve Inc. announced treatment this week of the first group of patients with the MitraClip system at the Karolinska University Hospital in Solna, Stockholm, Sweden.
September 03, 2009Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News
September 3, 2009 – Important new findings in patients with angina participating in the BEAUTIFUL study show that there is a 42 percent reduction in heart attack with Procoralan (ivabradine), as presented today at the European Society of Cardiology (ESC) Congress.
September 03, 2009
Technology
September 3, 2009 – ZOLL Medical Corp. received approval from the FDA to market and sell a new model of the LifeVest wearable defibrillator.
September 03, 2009Technology
The HI-TORQUE Versacore .035 Guide Wire is a peripheral guide wire is designed for routine diagnostic and device delivery for balloons and stents in peripheral vessels. Versacore features a soft, shapeable tip to provide safe access to peripheral lesions and enhanced visibility under fluoroscopy.
September 03, 2009Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News
September 3, 2009 – On Tuesday, Aug. 11, an 82-year old New Orleans resident with severe aortic stenosis successfully had a heart valve replaced at Ochsner Medical Center using the same technique as angioplasty, a far cry from the traditional open heart procedure.
September 03, 2009
Technology
The FoxCross PTA Catheter is a next-generation .035 balloon dilatation catheter is used to open peripheral arteries that have become blocked with plaque. The system is available in a wide variety of diameters (3-14 mm), balloon lengths (20-120 mm), and catheter lengths (50 cm, 80 cm and 135 cm) on an over-the-wire delivery platform.
September 03, 2009
News
September 3, 2009 – Abbott said last week it received approval from Health Canada for the XIENCE V Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease (CAD).
September 03, 2009Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
News
September 2, 2009 – Edwards Lifesciences Corp. said this week it completed enrollment in its 1,040-patient randomized controlled investigational device exemption (IDE) study of the Edwards SAPIEN transcatheter heart valve.
September 03, 2009News
September 3, 2009 – Boston Scientific Corp. said Tuesday long-term data from the Prevention of Sudden Cardiac Death II registry (PreSCD II) found that implantable cardioverter defibrillators (ICDs) were associated with a 44 percent reduction in all cause mortality when implanted in patients following myocardial infarction.
September 03, 2009
News
September 3, 2009 – The OASIS study group presented initial results of the CURRENT-OASIS 7 clinical trial Sunday at the European Society of Cardiology Congress in Barcelona, which did not show a statistical difference between the high-dose and standard-dose PLAVIX regimens, but subgroups did show some improvement.
September 03, 2009© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now